Groningen

• A Phase 2 Study of MK-4280A for the Treatment of Selected Solid Tumors Ended
  2023-505022-34-00 4 2024-03-27 Neoplasm malignant
• A first human dose study to assess the safety, tolerability, pharmacokinetics and target engagement of single doses of NNC6022-0001 in healt … Ended
  2023-505026-34-00 1 2024-03-26 Cardiometabolic diseases
• Investigating the safety, feasibility, and optimal dose of Adalimumab-680LT in IBD – GUIDE study Ended
  2023-508391-11-00 7 2024-03-21 Inflammatory Bowel Disease (IBD)
• A Phase 1, open label, randomized, 2-sequence, 2-period, crossover, single center study to evaluate the pharmacokinetics of follitropin alfa … Ended
  2023-507066-91-00 3 2024-03-19 Infertility
• A PHASE 1, OPEN-LABEL, RANDOMIZED, THREE-PERIOD, THREE-TREATMENT, BALANCED, SIX-SEQUENCE CROSSOVER STUDY TO DETERMINE THE RELATIVE BIOAVAILA … Ended
  2023-507661-26-00 3 2024-03-18 Alzheimer’s Disease
• Study to Assess the Effect of Food on the Pharmacokinetics of CA-4948 in Healthy Male Subjects Ended
  2023-509691-41-00 3 2024-03-14 Hematologic malignancies
• A proof of concept and dose-finding study of XXB750 in patients with heart failure Ended
  2023-504678-39-00 4 2024-03-13 Heart Failure
• A PHASE I, OPEN-LABEL, RANDOMIZED, ADAPTIVE, CROSS-OVER STUDY TO DETERMINE THE RELATIVE BIOAVAILABILITY OF NIZUBAGLUSTAT CAPSULES COMPARED T … Ended
  2023-510058-17-00 3 2024-03-12 Glycosphingolipid lysosomal storage disorders
• A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Selnoflast in Participants with Moderate to Severe Asthma Ended
  2023-504304-29-00 3 2024-03-01 Moderate to Severe Asthma
• A study in two groups of healthy male adult participants to assess how much test medicine (SAR441566) is taken up, degraded and removed by t … Ended
  2023-508030-33-00 8 2024-03-01 Healthy volunteers
• A SINGLE-CENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF REPEAT DOSES OF ARM210 IN HEAL … Ended
  2023-509086-20-00 3 2024-02-13 Cardiac arrhythmias
• "Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (MIRANDA)" Ended
  2023-505543-39-00 5 2024-02-12 Chronic Obstructive Pulmonary Disease (COPD)
• A RANDOMIZED, DOUBLE-BLIND, THREE-PART, TWO-PERIOD, TWO-SEQUENCE, SINGLE-DOSE, CROSS-OVER STUDY TO COMPARE THE PHARMACOKINETICS (PK), SAFETY … Ended
  2023-507877-17-00 2 2024-02-12 Not applicable, Healthy Volunteers
• ADME: A Study to Understand What the Body does to the Study Compound Called PF-07220060 When Taken by Healthy Adults. Ended
  2023-507074-40-00 3 2024-01-26 metastatic/advanced breast cancer
• A study to learn how BAY2927088 is taken up and handled by the body in healthy male participants Ended
  2022-502771-38-00 3 2024-01-24 Advanced non-small cell lung cancer with EGFR and/or HER2 mutations
• A study to test whether BI 456906 helps people living with overweight or obesity who do not have diabetes to lose weight Ended
  2022-502529-17-00 5 2024-01-18 Obesity
• A study to test whether BI 456906 helps people living with overweight or obesity who also have diabetes to lose weight Ended
  2022-502531-18-00 5 2024-01-18 Obesity
• A 12-week double-blind, multicentre, randomised, active-controlled, 2-arm, parallel-group clinical trial to evaluate the safety of CHF5993 p … Ended
  2023-503333-22-00 5 2024-01-15 Moderate to severe controlled asthma according to Step 4 and Step 5 of
• A study to investigate the mass balance, absolute bioavailability (BA), pharmacokinetics (PK), and metabolism of a single oral dose 60 mg [1 … Ended
  2023-506044-16-00 3 2023-12-14 There is no medical condition being investigated.
• A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release … Ended
  2023-505296-72-00 4 2023-12-12 Idiopathic Pulmonary Fibrosis (IPF)
• A study in healthy men to test how BI 1291583 is taken up by the body Ended
  2023-505683-11-00 3 2023-12-12 Healthy volunteer trial
• A study to investigate the pharmacokinetics of remibrutinib in CSF in healthy participants. Ended
  2023-506760-13-00 3 2023-12-11 Healthy
• A first-in-human, randomized, participant and investigator blinded, placebo-controlled single and multiple ascending dose study to assess th … Ended
  2023-505542-26-00 1 2023-11-30 Heart failure (HF)
• Radiotherapy plus xevinapant or placebo in older patients with locally advanced head and neck cancer Ended
  2022-502339-20-00 4 2023-11-15 Squamous cell carcinoma of head and neck

Showing 553–576 of 679 trials